Liye He

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5569590/publications.pdf

Version: 2024-02-01

		1039406	1281420	
11	834	9	11	
papers	citations	h-index	g-index	
11	11	11	2242	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	SynergyFinder: a web application for analyzing drug combination dose–response matrix data. Bioinformatics, 2017, 33, 2413-2415.	1.8	403
2	Methods for High-throughput Drug Combination Screening and Synergy Scoring. Methods in Molecular Biology, 2018, 1711, 351-398.	0.4	140
3	Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions. Cell Chemical Biology, 2018, 25, 224-229.e2.	2.5	124
4	Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. Cancer Research, 2018, 78, 2407-2418.	0.4	60
5	Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer. Npj Systems Biology and Applications, 2019, 5, 20.	1.4	32
6	Elevated expression of \$100A8 and \$100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. Leukemia, 2019, 33, 2548-2553.	3.3	25
7	TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples. Bioinformatics, 2015, 31, 1866-1868.	1.8	15
8	Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer. Briefings in Bioinformatics, 2021, 22, .	3.2	13
9	Systematic review of computational methods for drug combination prediction. Computational and Structural Biotechnology Journal, 2022, 20, 2807-2814.	1.9	13
10	Characterizing the Quality of Insight by Interactions: A Case Study. IEEE Transactions on Visualization and Computer Graphics, 2021, 27, 3410-3424.	2.9	7
11	Combined Targeting of BET Family Proteins and BCL2 Is Synergistic in Acute Myeloid Leukemia Cells Overexpressing S100A8 and S100A9. Blood, 2018, 132, 2634-2634.	0.6	2